Skip to content

Study · Animal study (in vivo) · mouse · 2000

18 results

Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice.

Mohan S, Kutilek S, Zhang C, Shen HG, Kodama Y, Srivastava AK, Wergedal JE, Beamer WG, Baylink DJ

Bone1 Oct 2000Cited by 74 (Europe PMC)

PMID11033441 (opens in a new tab)DOI10.1016/s8756-3282(00)00355-0 (opens in a new tab)PepBankPUB-11033441
Publisher pagePubMedAsk about this study
Jump to 18 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, daily PTH increased serum osteocalcin in a dose-dependent manner.

    In plain wordsIn mice, PTH increased serum osteocalcin compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum osteocalcin short-term
    Study

    mousen: not reported in source

    Mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 15 daysAs given in this study (mouse).

    Source sentences

    Summary
    Daily subcutaneous administration of PTH(1-34) for 15 days caused a dose-dependent increase in the serum osteocalcin level and bone extract alkaline phosphatase activity, markers of bone formation.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, daily PTH increased bone extract alkaline phosphatase activity in a dose-dependent manner.

    In plain wordsIn mice, PTH increased bone alkaline phosphatase activity compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone alkaline phosphatase
    Study

    mousen: not reported in source

    Mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 15 daysAs given in this study (mouse).

    Source sentences

    Summary
    Daily subcutaneous administration of PTH(1-34) for 15 days caused a dose-dependent increase in the serum osteocalcin level and bone extract alkaline phosphatase activity, markers of bone formation.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH(1-34) was more potent than PTH(2-34) for bone formation parameters.

    In plain wordsIn mice, PTH(1-34) stimulated bone formation parameters more potently than PTH(2-34).

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone formation potency
    Study

    mousen: not reported in source

    Mice
    Comparator
    PTH(2-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    PTH(2-34) was much less potent, whereas PTH(1-31) was equipotent in stimulating bone formation parameters in mice.
    2 context sentences
    Summary · context
    Daily subcutaneous administration of PTH(1-34) for 15 days caused a dose-dependent increase in the serum osteocalcin level and bone extract alkaline phosphatase activity, markers of bone formation.
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH(1-34) and PTH(1-31) were equipotent for bone formation parameters.

    In plain wordsIn mice, PTH(1-34) and PTH(1-31) had equal potency for bone formation parameters.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone formation potency
    Study

    mousen: not reported in source

    Mice
    Comparator
    PTH(1-31)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    PTH(2-34) was much less potent, whereas PTH(1-31) was equipotent in stimulating bone formation parameters in mice.
    2 context sentences
    Summary · context
    Daily subcutaneous administration of PTH(1-34) for 15 days caused a dose-dependent increase in the serum osteocalcin level and bone extract alkaline phosphatase activity, markers of bone formation.
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In mice, PTH increased serum calcium after 4 h.

    In plain wordsIn mice, PTH increased serum calcium compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum calcium
    Study

    mousen: not reported in source

    Mice
    Comparator
    Vehicle
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 4 hAs given in this study (mouse).

    Source sentences

    Summary
    PTH(1-34) caused significant increases in serum calcium (after 4 h) and tartrate-resistant acid phosphatase activity in bone extract (after 4 h), whereas PTH(2-34) and PTH(1-31) were less potent.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH increased tartrate-resistant acid phosphatase activity in bone extract after 4 h.

    In plain wordsIn mice, PTH increased bone tartrate-resistant acid phosphatase activity compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone tartrate-resistant acid phosphatase
    Study

    mousen: not reported in source

    Mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneous · 4 hAs given in this study (mouse).

    Source sentences

    Summary
    PTH(1-34) caused significant increases in serum calcium (after 4 h) and tartrate-resistant acid phosphatase activity in bone extract (after 4 h), whereas PTH(2-34) and PTH(1-31) were less potent.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In mice, PTH(1-34) increased serum calcium more potently than PTH(2-34).

    In plain wordsIn mice, PTH(1-34) increased serum calcium more potently than PTH(2-34).

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum calcium potency
    Study

    mousen: not reported in source

    Mice
    Comparator
    PTH(2-34)
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    PTH(1-34) caused significant increases in serum calcium (after 4 h) and tartrate-resistant acid phosphatase activity in bone extract (after 4 h), whereas PTH(2-34) and PTH(1-31) were less potent.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  8. 08AnimalAnimal study (in vivo)Safety outcome

    In mice, PTH(1-34) increased serum calcium more potently than PTH(1-31).

    In plain wordsIn mice, PTH(1-34) increased serum calcium more potently than PTH(1-31).

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum calcium potency
    Study

    mousen: not reported in source

    Mice
    Comparator
    PTH(1-31)
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    PTH(1-34) caused significant increases in serum calcium (after 4 h) and tartrate-resistant acid phosphatase activity in bone extract (after 4 h), whereas PTH(2-34) and PTH(1-31) were less potent.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH(1-34) increased bone tartrate-resistant acid phosphatase activity more potently than PTH(2-34).

    In plain wordsIn mice, PTH(1-34) increased bone acid phosphatase activity more potently than PTH(2-34).

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone acid phosphatase potency
    Study

    mousen: not reported in source

    Mice
    Comparator
    PTH(2-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    PTH(1-34) caused significant increases in serum calcium (after 4 h) and tartrate-resistant acid phosphatase activity in bone extract (after 4 h), whereas PTH(2-34) and PTH(1-31) were less potent.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH(1-34) increased bone tartrate-resistant acid phosphatase activity more potently than PTH(1-31).

    In plain wordsIn mice, PTH(1-34) increased bone acid phosphatase activity more potently than PTH(1-31).

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone acid phosphatase potency
    Study

    mousen: not reported in source

    Mice
    Comparator
    PTH(1-31)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    PTH(1-34) caused significant increases in serum calcium (after 4 h) and tartrate-resistant acid phosphatase activity in bone extract (after 4 h), whereas PTH(2-34) and PTH(1-31) were less potent.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH increased serum osteocalcin within 1 week and maintained this increase throughout 22 weeks.

    In plain wordsIn mice, PTH increased serum osteocalcin compared with baseline throughout treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum osteocalcin long-term
    Study

    mousen: not reported in source

    Mice
    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 microg/kg daily · subcutaneous · 22 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Weekly evaluations of serum osteocalcin levels demonstrated that daily injections of PTH(1-34) and PTH(1-31) at 80 microg/kg body weight increased serum osteocalcin levels within 1 week of the start of treatment, which were maintained during the entire 22 week treatment.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH(1-34) increased middiaphyseal femoral bone density more than PTH(1-31).

    In plain wordsIn mice, PTH(1-34) increased femoral bone density more than PTH(1-31).

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseMiddiaphyseal femoral bone density
    Study

    mousen: not reported in source

    Mice
    Comparator
    PTH(1-31)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 microg/kg daily · subcutaneous · 22 weeksAs given in this study (mouse).

    Measurements

    Density increase
    18%
    PTH(1-34) over vehicle
    Density increase
    9%
    PTH(1-31) over vehicle

    Source sentences

    Summary
    Assessment of bone density at the end of the treatment period with peripheral quantitated computed tomography (pQCT) revealed that PTH(1-34) caused a significantly greater increase in femoral bone density compared to PTH(1-31) at the middiaphysis (18% vs. 9% over vehicle control; p < 0.001).
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH(1-34) increased periosteal circumference versus vehicle.

    In plain wordsIn mice, PTH(1-34) increased periosteal circumference compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePeriosteal circumference
    Study

    mousen: not reported in source

    Mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 microg/kg daily · subcutaneous · 22 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Both PTH(1-34) and PTH(1-31) increased periosteal circumference compared to vehicle (p < 0.01) without a significant difference between the two treatments.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In mice, periosteal circumference did not differ significantly between PTH(1-34) and PTH(1-31).

    In plain wordsIn mice, periosteal circumference did not differ significantly between PTH(1-34) and PTH(1-31).

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePeriosteal circumference comparison
    Study

    mousen: not reported in source

    Mice
    Comparator
    PTH(1-31)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 microg/kg daily · subcutaneous · 22 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Both PTH(1-34) and PTH(1-31) increased periosteal circumference compared to vehicle (p < 0.01) without a significant difference between the two treatments.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH(1-34) reduced endosteal circumference more than PTH(1-31).

    In plain wordsIn mice, PTH(1-34) reduced endosteal circumference more than PTH(1-31).

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseEndosteal circumference
    Study

    mousen: not reported in source

    Mice
    Comparator
    PTH(1-31)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 microg/kg daily · subcutaneous · 22 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, PTH(1-34) caused a significantly greater reduction in endosteal circumference than PTH(1-31) (p < 0.001).
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH(1-34) significantly increased maximum load versus vehicle.

    In plain wordsIn mice, PTH(1-34) increased maximum load compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseMaximum load
    Study

    mousen: not reported in source

    Mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 microg/kg daily · subcutaneous · 22 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Both analogs significantly increased maximum load and area of moment of inertia over the vehicle group.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  17. 17AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH(1-34) significantly increased area of moment of inertia versus vehicle.

    In plain wordsIn mice, PTH(1-34) increased area of moment of inertia compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseArea of moment of inertia
    Study

    mousen: not reported in source

    Mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 microg/kg daily · subcutaneous · 22 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Both analogs significantly increased maximum load and area of moment of inertia over the vehicle group.
    1 context sentence
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.
  18. 18AnimalAnimal study (in vivo)Efficacy outcome

    In mice, PTH(1-34) increased middiaphyseal femoral bone density by 18% over vehicle control.

    In plain wordsIn mice, PTH increased femoral bone density compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseMiddiaphyseal femoral bone density versus vehicle
    Study

    mousen: not reported in source

    Mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 microg/kg body weight daily · Injection · 22 weeksAs given in this study (mouse).

    Measurements

    Density increase
    18%
    PTH(1-34) over vehicle control

    Source sentences

    Summary
    Assessment of bone density at the end of the treatment period with peripheral quantitated computed tomography (pQCT) revealed that PTH(1-34) caused a significantly greater increase in femoral bone density compared to PTH(1-31) at the middiaphysis (18% vs. 9% over vehicle control; p < 0.001).
    2 context sentences
    Summary · context
    Weekly evaluations of serum osteocalcin levels demonstrated that daily injections of PTH(1-34) and PTH(1-31) at 80 microg/kg body weight increased serum osteocalcin levels within 1 week of the start of treatment, which were maintained during the entire 22 week treatment.
    Summary · context
    In this study we used a mouse model system to compare the in vivo effects of parathyroid hormone(1-34) [PTH(1-34)] with that of PTH(1-31) or PTH(2-34) analogs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.